Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG . Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005; 28: 445–447.
Wu L, Hernandez-Bogantes E, Roca JA, Arevalo JF, Barraza K, Lasave AF . Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: a pilot study from the Pan-American Collaborative Retina Study Group. Retina 2011; 31: 298–303.
Androudi S, Tsironi E, Kalogeropoulos C, Theodoridou A, Brazitikos P . Intravitreal adalimumab for refractory uveitis-related macular edema. Ophthalmology 2010; 117: 1612–1616.
Acknowledgements
This study was supported in part by the Arevalo-Coutinho Foundation for Research in Ophthalmology, Caracas, Venezuela.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Additional information
Presented in part at the 44th Retina Society Annual Scientific Meeting, Rome, Italy, September 2011.
Rights and permissions
About this article
Cite this article
Arevalo, J., Serrano, M. & Wu, L. Combined inhibition of tumor necrosis factor (TNF) and vascular endothelial growth factor (VEGF) for the treatment of macular edema of various etiologies: a short-term pilot study. Eye 27, 569–571 (2013). https://doi.org/10.1038/eye.2012.301
Published:
Issue date:
DOI: https://doi.org/10.1038/eye.2012.301
This article is cited by
-
Update on intravitreal anti-tumor necrosis factor alpha therapies for ocular disorders
Journal of Ophthalmic Inflammation and Infection (2014)
